Loading...
•
Sep 30, 2020
Immunovant Q2 2021 Earnings Report
Reported financial results for the quarter ended September 30, 2020.
Key Takeaways
Immunovant reported financial results for the fiscal second quarter ended September 30, 2020. The company ended the quarter with approximately $444 million in cash. Net loss was $20.8 million, or $0.25 per common share.
Ended the quarter with approximately $444 million in cash.
Reported positive topline results from a randomized, placebo-controlled trial of IMVT-1401 in patients with moderate-to-severe Myasthenia Gravis (MG).
Appointed Michael Elliott, MBBS, Ph.D., as Chief Scientific Officer.
Strengthened balance sheet with approximately $188 million of net proceeds from a public equity offering.
Immunovant
Immunovant
Forward Guidance
The company plans to report results from the high-dose cohort of ASCEND WAIHA in the first quarter of calendar year 2021. They also plan to report results from ASCEND GO-2 in the first half of calendar year 2021 and announce three new indications for IMVT-1401 by August 2021.
Positive Outlook
- Report results from the high-dose cohort of ASCEND WAIHA in Q1 2021.
- Report results from ASCEND GO-2 in the first half of calendar year 2021.
- Announce three new indications for IMVT-1401 by August 2021.